IVIg治疗炎症性神经病患者的血栓栓塞风险:发生率与危险因素
该研究在30个月内随访接受规律IVIg治疗的炎症性神经病患者队列,评估IVIg是否增加动静脉血栓栓塞事件风险。结果显示血栓栓塞事件发生率高于基于医院住院数据确定的人群发生率,事件组血管危险因素更常见,但未发现IVIg给药相关因素贡献风险。作者认为IVIg在该队列中可能起小幅但叠加的作用,现有初级预防指南是否适用尚需更多证据。
要点
- 炎症性神经病IVIg队列血栓栓塞发生率高于医院住院数据推算的人群率
- 事件组血管危险因素更常见,未见IVIg给药因素贡献风险
- IVIg可能小幅增加血栓栓塞风险,现有初级预防指南适用性待证实
核心结论
- IVIg可能对炎症性神经病患者的血栓栓塞风险有小幅但叠加的作用。
- 是否应将现有初级预防指南用于该组患者,尚需更多证据明确。
研究设计与样本
- 在炎症性神经病患者队列中开展为期30个月的观察,对象为接受规律IVIg治疗的门诊患者。
- 将观察到的动静脉血栓栓塞事件发生率与基于医院住院数据确定的人群发生率进行比较。
主要发现
- 接受规律IVIg的炎症性神经病患者中,动脉和静脉血栓栓塞事件发生率高于基于医院住院数据确定的人群发生率。
- 血栓栓塞事件组的血管危险因素比无事件组更常见。
- 未发现任何IVIg给药相关因素对血栓栓塞风险有贡献。
临床怎么用
- 对接受规律IVIg的炎症性神经病患者,应评估并关注血管危险因素。
- IVIg给药因素未显示与血栓栓塞风险相关,是否启动初级预防需结合个体血管风险权衡。
局限性
- 原文摘要未报告样本量、事件数、效应量及置信区间等具体数据。
- 证据主要来自单中心队列观察,且作者指出该问题既往证据多来自非神经科队列且存在矛盾。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Our objective was to evaluate whether IV immunoglobulin (IVIg) increases the risk of thromboembolic events in neurology outpatients with inflammatory neuropathies, as there is conflicting evidence supporting this hypothesis, mainly from non-neurologic cohorts. We investigated this question over 30 months in our cohort of patients with inflammatory neuropathies receiving regular IVIg and found a greater incidence of arterial and venous thromboembolic events than population-based rates determined by hospital admissions data. Vascular risk factors were more common in the event group but there were no IVIg administration factors that contributed to the risk. This study suggests that IVIg may have a small but contributory role in determining thromboembolic risk in the inflammatory neuropathy cohort and more evidence is required before it is clear whether the current primary prevention guidelines are appropriate in this group of patients.
引用
- Kapoor M, Spillane J, Englezou C, et al. Thromboembolic risk with IVIg: Incidence and risk factors in patients with inflammatory neuropathy. Neurology. 2019. PMID: 31852814. doi:10.1212/WNL.0000000000008742
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。